These studies have now been supplemented by investigations to detect a viral pathogen in the gastrointestinal tract. Cytomegalovirus is found in the vast majority of HIV positive patients. Opportunistic disease, usually retinitis, caused by high viral loads of CMV are nowadays mostly prevented by ART, where this is available. However, there is extensive evidence that CMV infection, as opposed to overt disease, is not completely controlled by ART. It is known to infect endothelial, stromal and intestinal epithelial cells and may form ulcers to compromise the barrier function of the mucosa. It is known to disrupt tight junctions of retinal pigment epithelial cells, so might be able to do the same in epithelial cells of the gastrointestinal tract(3). It is possible therefore that it may contribute to the chronic gastrointestinal and systemic inflammation seen in HIV-positive patients.
A recent publication combined immunohistochemistry with in situ hybridisation on primary intestinal cells differentiated to form monolayers of polarised cells (4) . In this system, CMV decreased trans-epithelial electrical resistance, a method used to assess the integrity of an epithelial monolayer. Permeability was also changed when assessed by the ability of dextran labelled with a fluorescent dye to migrate across cells held in the compartments of a transwell apparatus. Only a few cells were CMV positive, raising the question of how an infection of limited scale could produce an effect across the whole epithelium. A contribution from interleukin-6 was identified, with the effect on epithelial integrity partially reduced by an antibody that blocked interleukin-6(4, 5). The antiviral drugs ganciclovir or letermovir reduced the effect of CMV on the epithelium. Parallel studies on biopsies of rectosigmoid tissue provided evidence that similar effects take place in vivo (4) . CMV proteins were readily detected in untreated HIV positive, CMV seropositive individuals. The quantity of cells expressing CMV proteins was reduced, but not abolished, in patients receiving ART. Tight junctions were disrupted and CMV DNA was present, thereby confirming productive CMV infection. Rectosigmoid biopsies from HIV negative, CMV seropositive individuals did not contain CMV proteins in intestinal epithelial cells, although neighbouring cells stained positive, illustrating that the presence of HIV could alter the distribution of CMV. Finally, biopsies from an HIV positive case of CMV colitis showed damage to tight junctions which was no longer apparent in biopsies taken after a course of valganciclovir had been completed(4).
Overall, this effect on gastrointestinal permeability should be classified along with the "indirect effects" of CMV which contrast with its "direct effects" of causing end-organ diseases such as retinitis. The indirect effects were originally described in allograft recipients and referred to CMV triggering graft rejections, contributing to the chronic inflammation that causes accelerated atherosclerosis or diverting immune responses to facilitate secondary bacterial or fungal infections (6) . The concept of indirect effects was subsequently discussed in HIV-positive patients as a way of explaining complex phenomena, including accelerated progression to full-blown AIDS and an excess of deaths, where it was called a cofactor effect (7, 8) . Cohort studies report a significant association between CMV and mortality with deaths reduced in those allocated to receive systemic ganciclovir rather than local therapy for retinitis (9) (10) (11) . A randomised placebo-controlled trial in HIV positive individuals showed that valganciclovir decreased the abundance of the activated T cells that are the hallmark of chronic inflammation (12) .
It is clear from this new paper and others that there are multiple ways for this opportunistic virus to interact with different organ systems to produce disease without declaring its presence. This research is to be welcomed as a way of starting to tease out the contributions that this common virus makes to medically important conditions in patients with complex medical backgrounds. The results demonstrate clearly that CMV persistence in the gastrointestinal tract can, like bacterial infections, provoke chronic, systemic inflammation in HIV positive individuals. The challenge now is to determine if CMV represents just one of many examples of an infectious agent provoking chronic inflammation or whether CMV induced cytokine response is a central feature of pathogenesis that allows bacterial antigens to cross into the systemic circulation. In other words, would reduction of CMV gastrointestinal infection in a randomised placebo-controlled trial of an anti-CMV drug like valganciclovir in HIV positive individuals maintain normal intestinal barrier function? If so, would this reduce the adverse effects attributed both to CMV and to those caused by bacteria? PD Griffiths ART = anti-retroviral therapy
